Primary Evaluation of Anticancer Activity of Nanocurcumin® Against Human Breast Cancer Cell Line, SkBr3

Year 2019, Volume 3, Issue 1, 13 - 19, 01.06.2019

Aminul ISLAM Leroy REBELLO Sreesudha CHEPYALA

Abstract

Breast cancer is a predominant ailment mostly impairing woman. Against the triple negative breast cancer xenografts, the curcumin in polymeric micelle form showed increased bioavailability, cytotoxicity and longer half-life, observed in in vitro studies (Cridge et al., 2013). In this study, in vitro anticancer activity of Nanocurcumin^® was evaluated against human breast cancer.

Keywords

Brest cancer, SkBr3 cell line, Nanocurcumin®

References

• 1. Cridge, B.J., Larsen, L., Rosengren, R.J. 2013. Curcumin and its derivatives in breast cancer: Current developments and potential for the treatment of drug-resistant cancers. Oncology Discovery, 2052, 1-6.2. Carey, L., Winer, E., Viale, G., Cameron, D., Gianni, L. 2010. Triple-negative breast cancer: disease entity or title of convenience? Nature Reviews Clinical Oncology, 7(12), 683-692.3. Yallapu, M.M., Othman, S.F., Curtis, E.T., Bauer, N.A., Chauhan, N., Kumar, D., Jaggi, M., Chauhan, S.C. 2012. Curcumin-loaded magnetic nanoparticles for breast cancer therapeutics and imaging applications. International Journal of Nanomedicine, 7, 1761-1779.4. Lin, W., Cooper, C., Camarillo, I. 2014 June 17-19. The effectiveness of electroporation-based nanocurcumin and curcumin treatments on human breast cancer cells. In: Proceedings of ESA annual meeting on electrostatics, University of Notre Dame, Notre Dame, Indiana., USA, Electrostatics Society of America, 1-7.